Trillium Medical Ventures, LLC

What Trillium Medical Ventures, LLC does

Trillium Medical Ventures, LLC (TMV) is a New York City-based scientific advisory firm founded in 1998 that provides end-to-end early-stage biotech asset sourcing and evaluation services. The firm operates as a long-term, exclusive partner to a Japanese-headquartered mid-size biopharmaceutical company and its worldwide subsidiaries, identifying and conducting scientific diligence on preclinical through Phase 2 assets, novel mechanisms, and drug discovery enabling technologies for the Japanese pharmaceutical market. Its 11–50 person team is led by two pharmaceutically trained co-founders — Lynne H. Parker, PhD (formerly Roche, Sandoz, Schering AG/Berlex) and Steven C. Bailey, PhD (formerly Hoechst, Schering AG/Berlex) — and combines drug discovery, preclinical development, and business development expertise under a founder-led ownership structure with no disclosed institutional investors.

TMV's offering is organized around six interconnected service modules: Technology Search & Evaluation, In-Licensing Opportunities, KOL Interviews, Competitive Intelligence, Scientific & Partnering Meetings, and Special Project Requests. The firm maintains a proprietary relational database spanning 25+ years of curated opportunities, with therapeutic coverage that has evolved from Chronic Diseases (1998–2023) to Rare/Genetic Diseases & Precision Medicine (2023–present), alongside continuous coverage of Drug Discovery Enabling Technologies including RNA targeting, targeted protein degradation, and computational/AI approaches. Marketing is conducted primarily through active presence at BIO International, BIO Europe, ChinaBio, JPM Week, and LSX rather than traditional digital channels.

Revenue is generated through professional services fees tied to the exclusive long-term partnership with the unnamed Japanese biopharma partner. No pricing, revenue, or financial details are publicly disclosed. Per the firm's own disclosures, TMV has sourced 9,400+ opportunities over its history and identifies >95 Strategic Research Opportunities per year, with >95% of opportunities rated "Valuable/Impressive" by its partner. The firm is privately held, founder-led, and operates as a B2B advisory with a US headquarters and global sourcing footprint spanning North America, Europe, and Greater China.

Name

Trillium Medical Ventures, LLC

Legal name

Trillium Medical Ventures

Website

https://trilliummed.com

Company type

Private

Founded year

1998

Operating status

Operating

Headcount range

11–50 employees

Short description

Trillium Medical Ventures is a New York-based scientific advisory firm founded in 1998 that provides end-to-end early-stage biotech asset sourcing and evaluation services exclusively to a Japanese mid-size biopharmaceutical partner, sourcing and scientifically validating preclinical through Phase 2 assets and platform technologies globally.

Ownership category

akta.pro rank

Product category

Life Sciences Consulting

NAICS

Other Scientific and Technical Consulting Services (54169), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Management Consulting Services (8742), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)

akta.pro secondary industry

Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH)

Keywords

• Drug discovery consulting
• Biotech asset evaluation
• Scientific advisory services
• In-licensing opportunities
• Competitive intelligence pharma

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Advisory and Evaluation Services: Revenue generated through providing scientific advisory, technology search & evaluation, and strategic business development services to pharmaceutical partners. Services include in-licensing opportunity identification, competitive intelligence, and custom scientific reports.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Trillium Medical Ventures is a US-based scientific advisory group providing end-to-end search and evaluation services for early-stage biotech assets on behalf of a Japanese-headquartered mid-size biopharmaceutical partner. The firm continuously sources, scientifically diligencess, and introduces preclinical through Phase 2 assets, novel mechanisms, and drug-discovery enabling technologies (e.g., AI/ML, RNA targeting, targeted protein degradation). Its offerings span technology search & evaluation, in-licensing identification, KOL interviews, competitive intelligence, conference-based partnering meetings, and custom special-project reports.

Product overview

Trillium Medical Ventures (TMV) provides a unified platform of end-to-end search and evaluation services for early-stage biotech assets. The core offering consists of six interconnected service modules: Technology Search & Evaluation (continuous sourcing of early-stage assets and platform technologies), In-Licensing Opportunities (identification of clinical/preclinical assets for the Japanese pharmaceutical market), KOL Interviews (expert scientific perspective from global academics and industry scientists), Competitive Intelligence (tracking of companies, compounds, and clinical trials), Scientific & Partnering Meetings (conference presence for emerging science and off-market opportunities), and Special Project Requests (custom reports for partner R&D and BD teams). TMV operates as a US-based scientific advisory group with 25+ years of experience, functioning as a long-term exclusive partner to a Japanese-headquartered mid-size biopharmaceutical company.

Differentiator

Problem solved

Functional benefit

Products and services

• Technology Search & Evaluation

Quantifiable outcome

• ~200 opportunities introduced to partners
• +3 more outcomes

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Japanese-headquartered mid-size biopharmaceutical company (unnamed)coreStrategic or Co-development Partner · 1 January 1998TMV serves as a long-term, exclusive partner to a Japanese-headquartered mid-size biopharmaceutical company and its World-Wide subsidiaries. TMV identifies and evaluates clinical and preclinical assets for the Japanese pharmaceutical market, providing end-to-end search and evaluation services including technology sourcing, scientific diligence, and business development contacts.

Scale indicators5 records

Recent moves4 records

Expansion highlights3 records

Direct peers

• Catenion: Berlin-based life sciences strategy firm advising pharma R&D and BD teams on portfolio decisions, target evaluation, and pipeline strategy — a comparable scientific advisory model with European geographic focus.
• Health Advances: Healthcare and life sciences strategy consulting firm advising pharma, biotech, and medtech on BD, licensing, and corporate strategy — directly comparable in serving pharma R&D and BD teams with deep scientific evaluation.
• Locust Walk: Life sciences-focused transaction advisory firm providing business development, licensing, and capital markets services to biotechs and pharma — directly comparable to TMV's search-and-evaluation advisory model, though broader in service scope.
• Back Bay Life Science Advisors: Boston-based life sciences advisory firm specializing in strategic partnering, licensing, and commercial assessments for biotech and pharma — overlaps directly with TMV's in-licensing opportunity identification and competitive intelligence work.
• ClearView Healthcare Partners: Strategy consulting firm focused exclusively on life sciences, supporting pharma BD, commercial, and R&D decisions — directly comparable in serving pharma partners with rigorous scientific and commercial evaluation.
• Alacrita: Life sciences consulting firm offering product development, commercial, and BD advisory to pharma and biotech — overlapping with TMV's scientific due diligence and asset evaluation services.
• Deallus Consulting: Life sciences strategy consultancy focused on competitive intelligence and therapy area strategy for pharma — overlapping with TMV's competitive intelligence and asset sourcing services.

Broad incumbents

• L.E.K. Consulting: Global management consulting firm with a large life sciences practice serving pharma BD, commercial, and R&D — operates at much larger scale and broader scope than TMV but competes for pharma advisory budgets.
• ZS Associates: Global professional services firm with a large pharma practice spanning commercial, R&D, and BD advisory — competes with TMV for pharma BD consulting engagements, though at much larger scale and broader scope.
• Charles River Associates: Global consulting firm with a Life Sciences practice providing strategy, litigation, and economic expertise to pharma and biotech — a broader incumbent competing for some of the same pharma strategy engagements.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Trillium Medical Ventures, LLC